Welcome to our dedicated page for Cardiol Therapeutics SEC filings (Ticker: CRDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiol Therapeutics Inc. filings document the formal disclosures of a Canadian life sciences issuer listed on Nasdaq and the TSX. Recent Form 6-K reports furnish press releases and exhibits covering CardiolRx clinical programs, including MAVERIC in recurrent pericarditis and ARCHER in acute myocarditis, as well as CRD-38 development, patent updates, and operating results summarized with audited financial statements and management discussion.
The filing record also documents governance and capital-structure matters, including annual general meeting notices, Class A common share voting mechanics, bought deal private placement terms, underwriting agreements, and warrant indenture provisions. These filings describe the company’s securities, financing arrangements, clinical-development disclosures, and foreign-issuer reporting framework.
Cardiol Therapeutics Inc. (CRDL) filed an amended short form base shelf prospectus under the MJDS, allowing offerings of up to US $150,000,000 of common shares, debt securities, warrants, subscription receipts, and units over a 25‑month period, including potential resales by selling securityholders. The company is a late‑stage life sciences issuer advancing CardiolRx for recurrent pericarditis (pivotal Phase III MAVERIC trial ongoing after a completed Phase II study) and CRD‑38 for inflammatory heart disease, with defined program budgets and timelines. Cash and cash equivalents were $26.1 million as of June 30, 2026, and Cardiol reports negative operating cash flow, expecting to use future proceeds for clinical development, general corporate purposes, and potential additional orphan or discovery programs, while acknowledging that the shelf size exceeds currently estimated milestone costs.
Cardiol Therapeutics Inc. (CRDL) reports that holders have exercised common share purchase warrants, providing the company with proceeds of over USD $7 million. Management states that this capital extends Cardiol’s cash runway into the first half of 2028 and funds operations through topline data from the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis.
Pursuant to its Acceleration Right on warrants issued in October 2025, Cardiol has accelerated the expiry of remaining warrants. Of the 5,712,500 warrants originally issued, 425,000 remained unexercised as of September 15, 2026, representing additional potential gross proceeds of USD $573,750. These warrants will now expire at 4:00 p.m. Eastern Time on October 16, 2026, after which any unexercised warrants will be cancelled for no consideration.
Cardiol Therapeutics Inc. (CRDL) is furnishing an updated Code of Conduct and Ethics that sets expectations for all directors, officers and employees regarding honesty, integrity, accountability and compliance with applicable laws, rules and regulations. The Code emphasizes avoiding actual or apparent conflicts of interest, protecting corporate assets, and maintaining confidentiality of non-public and price‑sensitive information, including information a reasonable investor would consider important.
The document requires employees to support accurate and timely disclosure in public reports, uphold reliable accounting and internal controls, and use email and IT systems only for legitimate purposes, with limited incidental personal use. Employees must report suspected violations or misconduct through management or the Audit Committee under the company’s Whistleblower Policy, with protection from retaliation for good‑faith reports. Cardiol’s board is responsible for monitoring compliance, reviewing the Code annually, and approving amendments or waivers, which will be publicly disclosed where required.
Cardiol Therapeutics Inc. (CRDL) furnished a Form 6-K providing a set of key commercial agreements and amendments. The company filed an exclusive Master Services Agreement with Dalton Pharma Services covering pharmaceutical development and manufacturing services, including detailed provisions on cGMP vs non-cGMP production, product rejection procedures, and dispute resolution using independent third-party testing.
Cardiol also filed a Development Agreement with Clinical Academic Research Organization, S.A. de C.V. (CARO), outlining development activities, governance of changes to the development plan, monthly status reporting, regulatory-cooperation obligations, and a compensation structure that includes CARO Compensation Warrants in lieu of regular invoicing until warrants are exercised. Additional exhibits provide an Exclusive Supply Agreement with Noramco, Inc. and multiple amendments and a payment extension, including scheduled raw-material payments for active pharmaceutical ingredient production, confirmation that the underlying supply agreement otherwise remains in force, and an amendment that will be null and void if a referenced Shoppers agreement is not signed by May 31, 2020. A notice of assignment states that Noramco has assigned all of its rights, liabilities, and obligations under the Exclusive Supply Agreement to Purisys LLC, an affiliate, effective December 30, 2019.
Cardiol Therapeutics Inc. (CRDL) filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement in the United States under the Multijurisdictional Disclosure System. Once the final prospectus is receipted and the registration statement is effective, these filings will permit Cardiol to offer various securities from time to time, having an aggregate initial offering price of up to US$150 million over a 25‑month period.
No securities are being offered in connection with this announcement, and the company is not obligated to conduct any offering under the shelf. At the request of staff of the Ontario Securities Commission, Cardiol added expanded narrative and component‑level detail to previously reported expenses and activities, without changing any reported revenues, expenses, net loss, cash flows, cash position, or financial position for any period.
The disclosure also highlights Cardiol’s late‑stage cardiovascular pipeline, including its lead drug candidate CardiolRx™ in recurrent pericarditis and acute myocarditis, and the CRD‑38 program targeting inflammatory heart disease, alongside FDA Orphan Drug Designation for CardiolRx™ in pericarditis.
Cardiol Therapeutics Inc. (CRDL) has filed a Form F-10 short form base shelf prospectus under the MJDS, allowing it and certain selling securityholders to offer and sell up to US $150,000,000 of Common Shares, Debt Securities, Warrants, Subscription Receipts, and Units from time to time over a 25‑month period. Securities may be sold via underwriters, dealers, agents, direct sales, acquisitions, and potentially “at‑the‑market distributions” for Common Shares only.
Cardiol states that the aggregate shelf capacity intentionally exceeds the estimated costs of its disclosed milestones, citing uncertainty in drug development, potential expansion opportunities, and possible in‑licensing or acquisitions. The company plans to use net proceeds generally to fund its clinical programs (including the Phase III MAVERIC trial and CRD‑38 development), working capital, and other corporate purposes, with exact terms and uses detailed in future prospectus supplements.
Cardiol Therapeutics Inc. (CRDL) reported that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026, at 10:30 a.m. EDT, with a live webcast available through the Investors section of its website.
The company describes itself as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, led by its small-molecule drug candidate CardiolRx™, which targets inflammasome pathway activation. Cardiol highlights its MAVERIC Program in recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial, for which CardiolRx™ has U.S. FDA Orphan Drug Designation. It also notes the completed Phase II ARCHER study in acute myocarditis and ongoing development of CRD-38, a subcutaneous formulation intended for inflammatory heart disease, including heart failure.
MMCAP International Inc. SPC and MM Asset Management Inc. report beneficial ownership of 21,310,099 Class A Common Shares of Cardiol Therapeutics Inc. as of June 30, 2026, representing 17.6% of the class.
The position consists of 15,598,560 shares plus 5,711,539 shares underlying warrants exercisable within 60 days. Both reporting persons have shared voting and dispositive power over all 21,310,099 shares and no sole voting or dispositive power.
Cardiol Therapeutics Inc. reported unaudited interim results for the three and six months ended June 30, 2026. The company remains pre-revenue and recorded a net loss of $6.1 million for the quarter and $16.9 million for the first half of 2026, compared with $8.4 million and $16.6 million in the prior-year periods. Operating expenses for the six months were driven by research and development of $8.1 million and general and administration of $9.5 million, including $4.2 million of share-based compensation.
Cardiol strengthened its balance sheet through a January 2026 unit financing that raised $14.85 million gross and warrant exercises of $2.49 million, increasing cash and cash equivalents to $26.1 million as of June 30, 2026 and total equity to $24.0 million. Management states this cash is expected to fund operations and planned milestones into Q4 2027.
Clinically, Cardiol advanced its lead drug CardiolRx™ in cardiovascular inflammation: the pivotal Phase III MAVERIC trial in recurrent pericarditis reached 75% enrollment, with target enrollment anticipated by the end of Q3 2026, and Phase II ARCHER myocarditis results were published in ESC Heart Failure. The company is also progressing CRD-38, budgeting about $4 million to complete IND-enabling studies by H1 2027.
Cardiol Therapeutics Inc., a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 9:00 a.m. EDT, with a live webcast available via its investor website.
The company highlights its lead small-molecule candidate CardiolRx™, which targets inflammasome pathway activation and is being evaluated in the MAVERIC Program for recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial, and in the completed Phase II ARCHER study in acute myocarditis. Cardiol also notes U.S. FDA Orphan Drug Designation for CardiolRx in pericarditis and ongoing development of CRD-38, a subcutaneous formulation aimed at inflammatory heart disease, including heart failure.